- Home
- CCCC vs PGP Comparison
CCCC vs PGP Comparison
Compare CCCC & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- PGP
- Stock Information
- Founded
- CCCC 2015
- PGP 2003
- Country
- CCCC United States
- PGP United States
- Employees
- CCCC N/A
- PGP N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- PGP Finance Companies
- Sector
- CCCC Health Care
- PGP Finance
- Exchange
- CCCC Nasdaq
- PGP Nasdaq
- Market Cap
- CCCC 104.4M
- PGP 97.1M
- IPO Year
- CCCC 2020
- PGP N/A
- Fundamental
- Price
- CCCC $2.46
- PGP $8.45
- Analyst Decision
- CCCC Buy
- PGP
- Analyst Count
- CCCC 2
- PGP 0
- Target Price
- CCCC $8.00
- PGP N/A
- AVG Volume (30 Days)
- CCCC 1.5M
- PGP 39.8K
- Earning Date
- CCCC 08-07-2025
- PGP 01-01-0001
- Dividend Yield
- CCCC N/A
- PGP 10.84%
- EPS Growth
- CCCC N/A
- PGP N/A
- EPS
- CCCC N/A
- PGP N/A
- Revenue
- CCCC $34,240,000.00
- PGP N/A
- Revenue This Year
- CCCC N/A
- PGP N/A
- Revenue Next Year
- CCCC N/A
- PGP N/A
- P/E Ratio
- CCCC N/A
- PGP N/A
- Revenue Growth
- CCCC 16.55
- PGP N/A
- 52 Week Low
- CCCC $1.09
- PGP $5.83
- 52 Week High
- CCCC $7.22
- PGP $7.81
- Technical
- Relative Strength Index (RSI)
- CCCC 59.48
- PGP 65.32
- Support Level
- CCCC $1.95
- PGP $8.35
- Resistance Level
- CCCC $2.94
- PGP $8.45
- Average True Range (ATR)
- CCCC 0.26
- PGP 0.07
- MACD
- CCCC 0.00
- PGP -0.00
- Stochastic Oscillator
- CCCC 51.52
- PGP 100.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.